Literature DB >> 8098587

Diabetes and development of tardive dyskinesia.

M G Woerner1, B L Saltz, J M Kane, J A Lieberman, J M Alvir.   

Abstract

Diabetes mellitus has been identified as a possible risk factor for tardive dyskinesia. The authors examined 160 elderly individuals who were beginning neuroleptic treatment; 24 had diabetes and 136 did not. After 43 weeks of neuroleptic exposure, the cumulative incidence rates of tardive dyskinesia were 54.1% (SE = 5.6%) for the diabetics and 25.6% (SE = 16.1%) for the nondiabetics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8098587     DOI: 10.1176/ajp.150.6.966

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  8 in total

1.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

2.  Tardive dyskinesia.

Authors:  Pratibha G Aia; Gonzalo J Revuelta; Leslie J Cloud; Stewart A Factor
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

3.  Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.

Authors:  J S Paulsen; M P Caligiuri; B Palmer; L A McAdams; D V Jeste
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

Review 4.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 5.  Neurophysiological endophenotypes across bipolar and schizophrenia psychosis.

Authors:  Gunvant K Thaker
Journal:  Schizophr Bull       Date:  2008-05-22       Impact factor: 9.306

6.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

7.  Tardive and spontaneous dyskinesia incidence in the general population.

Authors:  Ray M Merrill; Joseph L Lyon; Paul M Matiaco
Journal:  BMC Psychiatry       Date:  2013-05-28       Impact factor: 3.630

8.  Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus.

Authors:  Satyakam Mohapatra
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-05-31       Impact factor: 2.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.